Tag: BE BOLD study
-
BIMZELX vs SKYRIZI – one stands out in a head‑to‑head trial
A new head‑to‑head study found that bimekizumab (brand name BIMZELX) produced better short‑term joint improvement than risankizumab (brand name SKYRIZI) in adults with active psoriatic arthritis (PsA). The trial’s primary measure was ACR50 – a commonly used, fairly strict standard that means a patient has achieved at least a 50% improvement in joint signs and